Related Experiment Videos
[Diagnosis and therapy of chronic active hepatitis]
Insights
Corticosteroids are not suitable for all chronic active hepatitis (CAH) patients. Treatment decisions for CAH should be based on disease severity, with combination therapy offering a safer alternative for severe cases.
Area of Science:
- Hepatology
- Immunosuppressive therapy
- Internal Medicine
Context:
- Chronic active hepatitis (CAH) presents a heterogeneous clinical, biochemical, and histological picture.
- Current treatment paradigms for CAH lack a one-size-fits-all approach.
Purpose:
- To delineate treatment strategies for chronic active hepatitis based on disease severity.
- To evaluate the role of corticosteroids and combination therapy in managing CAH.
Summary:
- Distinguish CAH severity using histological, biochemical, and clinical criteria.
- Corticosteroids are indicated for severe CAH but generally not for mild CAH.
- Combination therapy (prednisolone and azathioprine) is effective with fewer side effects than high-dose prednisolone alone.
Impact:
- Guides clinical decision-making for CAH treatment, optimizing patient outcomes.
- Highlights the benefit of tailored therapeutic approaches in managing chronic liver disease.
- Supports the use of combination immunosuppression for severe CAH, reducing adverse events.
Abstract:
Chronic active hepatitis (CAH) as an entity covers a histologically, biochemically, and clinically heterogenous group of patients. Hence, there is no justification for treating all patients with this diagnosis with corticosteroids. On the basis of histological, biochemical, and clinical criteria, different degrees of severity of CAH can be distinguished. While corticosteroids appear to be indicated in severe CAH, they should, in general, not be administered in mild CAH. However, the course of disease must be carefully followed in these patients. In moderate CAH, the risk should be carefully weighed against the benefit of therapy in every individual patient, taking into account the severity of symptoms. In HBsAg-negative cases, a therapeutic trial of at least 6 months' duration is worthwhile. In HBsAg-positive patients, treatment with corticosteroids should be delayed and the course of the disease followed. Once the decision for corticosteroid therapy has been made, administration of 10 mg prednisolone and 50 mg azathioprine daily as a maintenance dose represents the therapy of choice. This combination is approximately as effective as 15--20 mg prednisolone alone, but is associated with a lower incidence of side effects.